Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States
- 17 November 2011
- journal article
- Published by Informa Healthcare in Journal of Medical Economics
- Vol. 15 (2), 264-275
- https://doi.org/10.3111/13696998.2011.644645
Abstract
(2012). Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States. Journal of Medical Economics: Vol. 15, No. 2, pp. 264-275. doi: 10.3111/13696998.2011.644645Keywords
This publication has 16 references indexed in Scilit:
- Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-upJAMA, 2011
- A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overviewCMAJ : Canadian Medical Association Journal, 2009
- Efficacy of Systemic Treatments for Moderate to Severe Plaque Psoriasis: Systematic Review and Meta-AnalysisDermatology, 2009
- Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trialsBritish Journal of Dermatology, 2008
- Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safetyBMC Musculoskeletal Disorders, 2008
- Systematic Review: Comparative Effectiveness and Harms of Disease-Modifying Medications for Rheumatoid ArthritisAnnals of Internal Medicine, 2008
- Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluationHealth Technology Assessment, 2007
- The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature reviewScandinavian Journal of Rheumatology, 2007
- Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical centerArthritis Care & Research, 2005
- Dose Intensification with Infliximab in Patients with Rheumatoid ArthritisAnnals of Pharmacotherapy, 2005